Meloxicam Cyclodextrin Complex for Faster Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief, which is exacerbated by inadequate response to prior migraine treatments.
Innovation Solution
A combination of meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD), a bicarbonate, and rizatriptan is used to form an inclusion complex, enhancing solubility and bioavailability, and administered simultaneously or within a short period to treat migraine and other pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is administered alone, then the drug structure is simple, but the aqueous solubility is poor leading to reduced bioavailability
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin structure provides a hydrophobic cavity that accommodates the meloxicam molecule, while the hydrophilic exterior enhances aqueous solubility. This mediator approach resolves the contradiction by enabling the poorly soluble drug to be transported effectively in aqueous environments.
Solution Approach 2:
The patent creates a composite pharmaceutical system combining meloxicam with cyclodextrin carriers. This composite approach integrates the therapeutic properties of meloxicam with the solubility-enhancing properties of cyclodextrins, resulting in a formulation that achieves both drug efficacy and improved bioavailability through enhanced aqueous solubility.
2Speed
If meloxicam is administered alone, then the formulation is simple, but the onset of pain relief is slow
Solution Approach 1:
The cyclodextrin inclusion complex acts as a mediator that facilitates faster dissolution and absorption of meloxicam. By pre-organizing the drug within the cyclodextrin cavity, the formulation achieves rapid release upon contact with aqueous environments, thereby accelerating the onset of pain relief without requiring complex delivery systems.
3Reliability
If conventional migraine treatments are used, then the treatment approach is standard, but the response is inadequate in many patients
Solution Approach 1:
The patent changes the physicochemical parameters of meloxicam through cyclodextrin complexation, transforming it from a poorly soluble compound to a highly bioavailable formulation. This parameter change enables the drug to achieve therapeutic concentrations more reliably and faster, improving treatment effectiveness for patients who previously responded inadequately to conventional treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination provides rapid, sustained, and statistically significant pain relief, reducing the need for rescue medication and improving treatment outcomes in patients with a history of inadequate responses to prior treatments.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.